[breadcrumb_custom]

Does AbCellera Biologics Inc (NASDAQ:ABCL) Look Expensive At $5.11? Here’s How To Know.

In last trading session, AbCellera Biologics Inc (NASDAQ:ABCL) saw 0.89 million shares changing hands with its beta currently measuring 0.38. Company’s recent per share price level of $5.11 trading at $0.09 or 1.79% at ring of the bell on the day assigns it a market valuation of $1.48B. That closing price of ABCL’s stock is at a discount of -107.24% from its 52-week high price of $10.59 and is indicating a premium of 24.27% from its 52-week low price of $3.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.27 million shares which gives us an average trading volume of 1.47 million if we extend that period to 3-months.

AbCellera Biologics Inc (NASDAQ:ABCL) trade information

Upright in the green during last session for gaining 1.79%, in the last five days ABCL remained trading in the green while hitting it’s week-highest on Wednesday, 02/07/24 when the stock touched $5.11 price level, adding 1.54% to its value on the day. AbCellera Biologics Inc’s shares saw a change of -10.51% in year-to-date performance and have moved 2.00% in past 5-day. AbCellera Biologics Inc (NASDAQ:ABCL) showed a performance of -9.24% in past 30-days. Number of shares sold short was 25.07 million shares which calculate 18.17 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

AbCellera Biologics Inc (ABCL) estimates and forecasts

Statistics highlight that AbCellera Biologics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -13.10% of value to its shares in past 6 months, showing an annual growth rate of -196.00% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -30.00% in the current quarter and calculating 14.30% increase in the next quarter. This year revenue growth is estimated to fall -92.10% from the last financial year’s standing.

10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $8.88 million for the same. And 5 analysts are in estimates of company making revenue of $13.84 million in the next quarter that will end on Mar 2024. Company posted $21.55 million and $12.19 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -58.80% while estimating it to be 13.50% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 308.35% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -191.96% while estimates for its earnings growth in next 5 years are of 10.00%.

ABCL Dividends

AbCellera Biologics Inc is more likely to be releasing its next quarterly report on February 20 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

AbCellera Biologics Inc (NASDAQ:ABCL)’s Major holders

Insiders are in possession of 28.17% of company’s total shares while institution are holding 45.24 percent of that, with stock having share float percentage of 62.99%. Investors also watch the number of corporate investors in a company very closely, which is 45.24% institutions for AbCellera Biologics Inc that are currently holding shares of the company. Baillie Gifford and Company is the top institutional holder at ABCL for having 26.36 million shares of worth $170.32 million. And as of Jun 29, 2023, it was holding 9.11% of the company’s outstanding shares.

The second largest institutional holder is Baker Brothers Advisors, LLC, which was holding about 16.45 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 5.69% of outstanding shares, having a total worth of $106.27 million.

On the other hand, Smallcap World Fund and American Funds Insurance Ser-Asset Allocation Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 5.48 million shares of worth $35.4 million or 1.89% of the total outstanding shares. The later fund manager was in possession of 2.87 million shares on Jun 29, 2023, making its stake of worth around $18.55 million in the company or a holder of 0.99% of company’s stock.

On Key

Related Posts